How much funding has PepGen raised?

PepGen has raised $160.4M in total funding, most recently a Series B round.

Who are PepGen's investors?

PepGen's investors include RA Capital Management, Oxford Science Enterprises, SVB Leerink, Stifel Financial, CureDuchenne Ventures.

Where is PepGen headquartered?

PepGen is headquartered in Boston, Massachusetts, United States.

What industry is PepGen in?

PepGen operates in Healthcare, Biotech.

PepGen

IPO

Better Technology. Better Delivery.

Public · Boston, United States · Founded 2018 · $160.4M raised

Healthcare

Biotech

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: pepgen.com

Total Funding: $160.4M
Last Round: $112.5M Series BAug 2021
Rounds: 3
Type: Public

About

PepGen is a clinical-stage biotechnology company advancing a new generation of oligonucleotide therapies for neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen addresses the delivery challenges of prior-generation therapies by enabling deep tissue penetration and high uptake in key muscle tissues. The company's lead programs target myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy, with plans to expand into additional indications.

Summary

PepGen is a Healthcare company based in Boston, United States, founded in 2018. It has raised $160.4M in total across 3 rounds, most recently a $112.5M Series B round in Aug 2021. Investors include RA Capital Management, Oxford Science Enterprises and SVB Leerink.